Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

Corporate Breaking News

Home : Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003

Jan 04 2022	Harbour BioMed Announces Dosing of First Patient of Two Phase I Trials for Next-Generation Anti-CTLA-4 Antibody HBM4003
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 4, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, its next generation anti-CTLA-4 fully human heavy-chain only antibody (HCAb), HBM4003, has completed the first dosing of first patient in two...


Source:https://www.prnewswire.com:443/news-releases/harbour-biomed-announces-dosing-of-first-patient-of-two-phase-i-trials-for-next-generation-anti-ctla-4-antibody-hbm4003-301453375.html

Related News
» IFS retains status as a Leader in IDC MarketScape for Worldwide Manufacturing Field Service Management » KIA AMERICA SURPASSES 700,000 UNITS FOR THE FIRST TIME AND COMPLETES BEST SALES YEAR IN COMPANY HISTORY